Patient-Reported Experiences of Sapropterin in PKU in the UK
Research type
Research Study
Full title
From Guidelines to Practice: Patient-Reported Experiences of Sapropterin in PKU in the UK
IRAS ID
370078
Contact name
Anita MacDonald
Contact email
Sponsor organisation
Birmingham Children's Hospital
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
Phenylketonuria (PKU) is a rare inherited condition that affects how the body processes protein. People with PKU cannot break down an amino acid called phenylalanine, which can build up in the blood and affect brain development and thinking skills if not well controlled. To stay healthy, most people with PKU need to follow a very strict low‑protein diet and take special protein substitutes every day. This can be challenging and can place a heavy burden on individuals and families.
Sapropterin (also known as BH4) is a medication that can help some people with PKU by improving the activity of the enzyme they are missing. For those who respond to it, sapropterin can lower blood phenylalanine levels and allow more natural protein in the diet. Clinical guidelines recommend offering sapropterin testing to see who might benefit. However, in the UK, access to sapropterin varies between centres, and families report different experiences of being informed, tested, or supported.
This study aims to understand these experiences directly from people with PKU and from parents or carers of children with PKU. We want to learn:
• If people are told about sapropterin and offered testing
• How testing and dosing are carried out in practice
• How supported families feel when using sapropterin
• What barriers or challenges they face when trying to access treatmentREC name
East of England - Cambridge Central Research Ethics Committee
REC reference
26/EE/0093
Date of REC Opinion
14 Apr 2026
REC opinion
Further Information Favourable Opinion